The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Dec 17

PMID 39682109

Authors

Irini Yacoub

Kareem Rayn

J Isabelle Choi

Richard Bakst

Arpit Chhabra

Joshua Y Qian

Peter Johnstone

Charles B Simone 2nd

Affiliations

Soon will be listed here.

Abstract

Introduction: Skin cancer impacts a significant proportion of the population. While surgical management is often the mainstay of treatment, advanced or metastatic cutaneous malignancies require additional local and/or systemic therapies.

Methods: A review of the literature was performed studying the use of radiation therapy, chemotherapy, and immunotherapy for locally advanced or metastatic cutaneous malignancies.

Results: A summary of the present literature on the management of locally advanced or metastatic cutaneous malignancies is presented across cutaneous head and neck basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The addition of multidisciplinary therapies to resection is often associated with improved outcomes.

Conclusion: The management of cutaneous head and neck malignancies requires an approach integrating multiple specialties, to optimize outcomes and minimize toxicities.

References

Bhatia S, Storer B, Iyer J, Moshiri A, Parvathaneni U, Byrd D . Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016; 108(9). PMC: 6059142. DOI: 10.1093/jnci/djw042. View

Eggermont A, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H . Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19):1845-1855. PMC: 5648545. DOI: 10.1056/NEJMoa1611299. View

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6. View

Ascierto P, Long G, Robert C, Brady B, Dutriaux C, Di Giacomo A . Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2018; 5(2):187-194. PMC: 6439558. DOI: 10.1001/jamaoncol.2018.4514. View

Williams L, Mancuso A, Mendenhall W . Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. 2001; 49(4):1061-9. DOI: 10.1016/s0360-3016(00)01407-3. View

Ligtenberg K, Hu J, Damsky W, Olino K, Kluger H, Clune J . Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Rep. 2020; 6(7):628-633. PMC: 7317689. DOI: 10.1016/j.jdcr.2020.05.010. View

Sullivan R, LoRusso P, Boerner S, Dummer R . Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015; :177-86. DOI: 10.14694/EdBook_AM.2015.35.177. View

Cramer J, Suresh K, Sridharan S . Completion lymph node dissection for merkel cell carcinoma. Am J Surg. 2020; 220(4):982-986. DOI: 10.1016/j.amjsurg.2020.02.018. View

Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers B . Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015; 16(9):1049-1060. DOI: 10.1016/S1470-2045(15)00187-4. View

10.

Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E . Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI: 10.1056/NEJMoa1904059. View

11.

Agelli M, Clegg L . Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003; 49(5):832-41. DOI: 10.1016/s0190-9622(03)02108-x. View

12.

Fenig E, Brenner B, Katz A, Rakovsky E, Hana M, Sulkes A . The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer. 1997; 80(5):881-5. DOI: 10.1002/(sici)1097-0142(19970901)80:5<881::aid-cncr8>3.0.co;2-o. View

13.

Reijers I, Menzies A, van Akkooi A, Versluis J, van den Heuvel N, Saw R . Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022; 28(6):1178-1188. DOI: 10.1038/s41591-022-01851-x. View

14.

Wong W, Stahl K, Olecki E, Perez Holguin R, Pameijer C, Shen C . Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma. J Surg Res. 2021; 266:168-179. DOI: 10.1016/j.jss.2021.03.062. View

15.

Guthrie Jr T, McElveen L, Porubsky E, Harmon J . Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985; 55(8):1629-32. DOI: 10.1002/1097-0142(19850415)55:8<1629::aid-cncr2820550802>3.0.co;2-i. View

16.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

17.

Malone J, Fedok F, Belchis D, Maloney M . Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat J. 2000; 79(7):511-5, 518-9. View

18.

Mendenhall W, Amdur R . Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol. 2001; 22(6):387-90. DOI: 10.1053/ajot.2001.28083. View

19.

Tarantola T, Vallow L, Halyard M, Weenig R, Warschaw K, Grotz T . Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2012; 68(3):425-32. DOI: 10.1016/j.jaad.2012.09.036. View

20.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View